GlassScriptPhysician profile
Melissa Medina
NPI 1639587439
$12,532.92
in general payments reported to CMS, 2019-2025
34 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,461 · 2022: $2,367 · 2023: $2,146 · 2024: $6,172 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,964 · Consulting Fee: $1,713 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,620 · Travel and Lodging: $379 · Education: $28.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,964.44 |
| Consulting Fee | $1,712.74 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,620.00 |
| Travel and Lodging | $379.17 |
| Education | $28.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $3,367.57 | 2024 | Rezdiffra, Resmetirom |
| Abbvie INC. | $1,270.67 | 2021-2025 | |
| Janssen Biotech, INC. | $921.47 | 2021-2025 | Stelara, Simponi, Remicade |
| Redhill Biopharma INC. | $833.43 | 2021-2024 | Talicia, Aemcolo, Movantik |
| Abbott Laboratories | $782.93 | 2023-2024 | Thoratec Heartmate 3 Lvas Implant Kit, 2nd Gen Centrimag Primary Console |
| Takeda Pharmaceuticals U.S.A., INC. | $628.61 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $510.83 | 2022-2024 | |
| Pfizer INC. | $449.64 | 2021-2024 | |
| Gilead Sciences, INC. | $416.22 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $416.19 | 2022-2024 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $393.43 | 2021-2024 | Xifaxan, Trulance |
| Lilly USA, LLC | $373.00 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $302.21 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $295.93 | 2021-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $212.11 | 2024-2025 | Voquezna |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $152.98 | 2023-2025 | Vegzelma, Yuflyma, Zymfentra |
| Evoke Pharma, INC. | $150.59 | 2021-2024 | Gimoti |
| Celgene Corporation | $125.75 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $117.92 | 2023-2024 | Sucraid, Sucraid |
| Braintree Laboratories, INC. | $97.66 | 2021-2025 | Suflave, Sutab |
| Nestle Healthcare Nutrition INC. | $96.37 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $92.82 | 2021-2024 | Dificid |
| Daiichi Sankyo INC. | $89.12 | 2021-2023 | Injectafer |
| Ipsen Biopharmaceuticals, INC | $71.09 | 2024 | Iqirvo |
| Amag Pharmaceuticals, INC. | $64.11 | 2021-2022 | |
| Shield Therapeutics INC | $55.16 | 2023-2024 | Accrufer |
| Ferring Pharmaceuticals INC. | $54.41 | 2023 | Rebyota |
| Fresenius Kabi USA, LLC | $48.20 | 2023 | Idacio |
| Aimmune Therapeutics, INC. | $47.51 | 2024 | |
| Intercept Pharmaceuticals, INC. | $25.05 | 2021 | |
| Albireo Pharma, INC. | $24.91 | 2024 | Iqirvo |
| Chiesi USA, INC. | $18.17 | 2022 | |
| Amgen INC. | $14.32 | 2021 | |
| Alnylam Pharmaceuticals INC. | $12.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Medina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.